Clinical trial · people
Setmelanotide: people with MC4R gene changes lost weight in 28 days
Checked against the paper Clinical trialPublished by PepVault
The takeaway
Setmelanotide produced weight loss in people with MC4R variants over 28 days, though less than in people with POMC defects, so how well it works may depend on which part of this pathway is affected.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2017
- Journal
- Mol Metab
What they tested
The team wanted to know whether setmelanotide, a drug that switches on the MC4R receptor, can cause weight loss in people whose obesity comes with changes in the MC4R gene.
How the study was done
The work combined cell tests on mutant MC4R receptors, studies in normal mice and mice missing one or both copies of MC4R, a review of 369 published MC4R variants, and a 28-day phase 1b clinical trial in obese people carrying MC4R variants. Weight loss in that group was compared with people who have POMC defects and with obese controls.

Model. Individual results vary.
What they found
In the 28-day trial, people with obesity and MC4R variants lost weight on setmelanotide. People with POMC defects, which sit earlier in the same signaling path, lost significantly more weight than people with MC4R deficiency or obese controls. In mice, normal animals seemed more sensitive to the drug than mice missing one copy of MC4R, and mice missing both copies did not respond. In cells, setmelanotide was significantly more potent at MC4R than alpha-MSH, the body's own signal, and restored signaling to an outsized degree in some MC4R mutants with severe defects.
What it doesn’t show
This was a short, early-stage trial lasting 28 days, and the authors say more studies are needed to learn whether the weight loss is large enough to matter for health in some people with MC4R deficiency. The mouse and cell results are not human results.
The paper
Collet et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.